Dr. Reddy's Laboratories (RDY) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 285.3% versus a gain of 7.0%. Over five years, RDY leads with a +18.2% price change compared with -42.0% for SYRE. Dr. Reddy's Laboratories is the larger company by market cap ($12.41 billion vs $8.88 billion), about 1.4 times the size.
Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Spyre Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RDY | SYRE |
|---|---|---|
| Share price | $14.89 | $93.47 |
| Market cap | $12.41B | $8.88B |
| 1-day change | +0.40% | -4.26% |
| YTD return | +6.05% | +185.32% |
| 1-year return | +7.05% | +285.28% |
| 5-year return | +18.19% | -42.03% |
| P/E ratio (TTM) | 41.36 | — |
| Forward P/E | 22.47 | — |
| EPS (TTM) | $0.36 | $-2.49 |
| Dividend yield | 53.73% | 0.00% |
| Annual dividend | $8.00 | $0.00 |
| Revenue (latest FY) | $3.81B | $0 |
| Revenue growth (YoY) | +13.76% | — |
| Net income (latest FY) | $663.00M | $-155.20M |
| Gross margin | 58.51% | — |
| Operating margin | 22.09% | — |
| Net margin | 17.40% | — |
| 52-week high | $15.67 | $110.64 |
| 52-week low | $11.36 | $24.58 |
| Distance from 52-week high | -4.98% | -15.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +0.20% | +32.52% |
| Average volume | 2.85M | 1.26M |
| Shares outstanding | 833.66M | 94.97M |
| Employees | 27,527 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed RDY by 278.2 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (53.73% vs 0.00%).
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
RDY vs SYRE FAQ
Which is bigger, Dr. Reddy's Laboratories or Spyre Therapeutics?
Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $12.41B compared with $8.88B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, RDY or SYRE?
SYRE returned +285.28% over the past 12 months, compared with +7.05% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Dr. Reddy's Laboratories or Spyre Therapeutics?
Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Spyre Therapeutics does not currently pay a regular dividend.
Are Dr. Reddy's Laboratories and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.